Algernon NeuroScience reports successful second cohort dosing in DMT clinical study
News release
by
Algernon Pharmaceuticals Inc.
Vancouver
|
April 05, 2023 01:03 PM Eastern Daylight Time
Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news the company’s subsidiary Algernon Neuroscience has completed dosing of the second cohort in the Phase 1 clinical study of DMT.
Moreau tells Proactive the study is to identify the safety and tolerability of DMT when administered as an intravenous bolus followed by a prolonged infusion of 6 hours which has never been studied clinically.
Contact Details
Proactive Investors
+1 604-688-8158
